Get the app!
Back to Trades
Other4

Kailera Therapeutics, Inc.

KLRA

Total Value
$0

Company Information

Ticker Symbol
KLRA
CIK
0002096997

Insider Information

Role
10% Owner
10% Owner

Filing Details

Filing Date
Apr 22, 2026
Transaction Date
Apr 20, 2026
Accession Number
0001104659-26-046276
Form Type
4

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Apr 20, 2026Common Stock9,477,719C
Apr 20, 2026Common Stock2,034,133C

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Apr 20, 2026Derivative4,968,789C
Apr 20, 2026Derivative708,814C

Footnotes

  1. (F1)The reported securities are directly held by Hengrui (USA) Ltd. Hengrui (USA) Ltd. is a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  2. (F2)The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.